Climb Bio (CLYM) closed at $12.25 on November 11, 2026, up 4.3% from the previous close, on volume of 1,328,800 shares (30-day average 1,152,793).
Data as of November 11, 2026.
| # | Date | Strategy | Legs | Contracts | Position |
|---|
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 10, 2026. See the 10 largest for 30, 60 and 90 days
TipRanks (Mon, 9-Nov 9:00 PM ET)
Climb Bio’s Buy Rating Reiterated as Pipeline Catalysts Advance; Price Target Unchanged at $30
TipRanks (Mon, 9-Nov 7:16 AM ET)
Truist Financial Reaffirms Their Buy Rating on Climb Bio (CLYM)
TipRanks (Fri, 6-Nov 10:03 AM ET)
Climb Bio Reports Third Quarter 2026 Financial Results and Provides Business Updates
Globe Newswire (Thu, 5-Nov 7:00 AM ET)
Globe Newswire (Wed, 4-Nov 9:00 AM ET)
Climb Bio to Present at Guggenheim 3rd Annual Healthcare Innovation Conference
Globe Newswire (Mon, 2-Nov 7:00 AM ET)
Globe Newswire (Sat, 24-Oct 7:30 PM ET)
Globe Newswire (Fri, 23-Oct 4:01 PM ET)
Globe Newswire (Fri, 2-Oct 9:30 AM ET)
Climb Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics for patients with immune-mediated diseases. Its pipeline includes Budoprutug, an anti-CD19 monoclonal antibody being developed for B-cell mediated diseases such as primary membranous nephropathy, immune thrombocytopenia, and systemic lupus erythematosus, and CLYM116, an anti-APRIL monoclonal antibody being developed for the treatment of IgA nephropathy.
Climb Bio trades on the NASDAQ stock market under the symbol CLYM.
As of November 11, 2026, CLYM stock price climbed to $12.25 with 1,328,800 million shares trading.
CLYM has a beta of 1.97, meaning it tends to be more sensitive to market movements. CLYM has a correlation of 0.05 to the broad based SPY ETF.
CLYM has a market cap of $703.59 million. This is considered a Small Cap stock.
The top ETF exchange traded funds that CLYM belongs to (by Net Assets): VTI, XBI, IWM, VXF, VFMO.
CLYM has outperformed the market in the last year with a price return of +580.6% while the SPY ETF gained +12.6%. However, in the short term, CLYM had mixed performance relative to the market. It has underperformed in the last 3 months, returning -9.5% vs -1.5% return in SPY. But in the last 2 weeks, CLYM shares have fared better than the market returning +28.0% compared to SPY -1.3%.
CLYM support price is $11.05 and resistance is $12.43 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CLYM shares will trade within this expected range on the day.
